Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | NCF1 | P14598 | 2/20 | 0.49 |
| ▸ | NOS1 | P29475 | 2/20 | 0.44 |
| ▸ | NOS2 | P35228 | 2/20 | 0.44 |
| ▸ | DNM2 | P50570 | 2/20 | 0.43 |
| ▸ | XIAP | P98170 | 1/20 | 0.41 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | TOP2A | P11388 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | TERT | O14746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6027125 | 0.81 | CYP2C19 (0.57) | HRH3CYP2C19NCF1DNM2 | |
| SCHEMBL11456527 | 0.79 | CYP2C19 (0.56) | HRH3CYP2C19NCF1NOS1NOS2 | |
| SCHEMBL11447765 | 0.79 | CYP2C19 (0.56) | HRH3CYP2C19NCF1DNM2IRAK4 | |
| SCHEMBL11446725 | 0.79 | CYP2C19 (0.56) | HRH3CYP2C19NCF1DNM2IRAK4 | |
| SCHEMBL16790977 | 0.78 | HRH3 (0.43) | HRH3NOS1NOS2XIAPBIRC2 | |
| SCHEMBL13403447 | 0.77 | MEN1 (0.51) | XIAPBIRC2ALDH1A1 | |
| SCHEMBL8396192 | 0.77 | TLR8 (0.58) | HRH3XIAPBIRC2ALDH1A1 | |
| SCHEMBL11456718 | 0.77 | CYP2C19 (0.53) | HRH3CYP2C19NCF1DNM2IRAK4 | |
| SCHEMBL11185939 | 0.77 | CYP2C19 (0.53) | HRH3CYP2C19DNM2IRAK4PIM1 | |
| SCHEMBL22011153 | 0.77 | HRH4 (0.40) | HRH3NOS2XIAPBIRC2IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048891-A1 | METASUBSTITUTED THIAZOLIDINONES, THEIR MANUFACTURE AND USE AS A DRUG | SCHULZE KLAUSE | 2010-02-25 | — | — | US | disclosed |
| US-20100048891-A1 | METASUBSTITUTED THIAZOLIDINONES, THEIR MANUFACTURE AND USE AS A DRUG | SCHULZE KLAUSE | 2010-02-25 | — | — | US | disclosed |
| US-20100048891-A1 | METASUBSTITUTED THIAZOLIDINONES, THEIR MANUFACTURE AND USE AS A DRUG | SCHULZE KLAUSE | 2010-02-25 | — | — | US | disclosed |
| US-7196104-B2 | Thiazolyl urea compounds and methods of uses | AMGEN, INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-20070015759-A1 | Metasubstituted thiazolidinones, their manufacture and use as a drug | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-01-18 | — | — | US | disclosed |
| US-20070015759-A1 | Metasubstituted thiazolidinones, their manufacture and use as a drug | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-01-18 | — | — | US | disclosed |
| EP-1309589-B1 | UREA COMPOUNDS AND METHODS OF USES | AMGEN INC (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1619184-A2 | Urea compounds as kinase inhibitors | Amgen, Inc. (US) | 2006-01-25 | — | — | EP | disclosed |
| US-20040044044-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2004-03-04 | — | — | US | disclosed |
| US-6645990-B2 | For prophylaxis and therapy of diseases, such as cell proliferation or apoptosis mediated diseases | AMGEN INC. | 2003-11-11 | — | — | US | disclosed |
| EP-1309589-A2 | UREA COMPOUNDS AND METHODS OF USES | Amgen Inc. (US) | 2003-05-14 | — | — | EP | disclosed |
| US-20020193405-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2002-12-19 | — | — | US | disclosed |
| US-20020173507-A1 | Urea compounds and methods of uses | AMGEN INC. | 2002-11-21 | — | — | US | disclosed |
| WO-2002014311-A2 | UREA COMPOUNDS AND METHODS OF USES | AMGEN INC. (US) | 2002-02-21 | — | — | WO | disclosed |
| US-4203988-A | ANTISECRETORY AGENTS | MERCK & CO., INC. (US) | 1980-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048891-A1 | METASUBSTITUTED THIAZOLIDINONES, THEIR MANUFACTURE AND USE AS A DRUG | PLK2, PDXK, PLK4 | HRH3 4815/4885CYP2C19 1086/4885NCF1 4191/4885 |
| US-20020193405-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | HRH3 3754/4885CYP2C19 1334/4885NCF1 2374/4885 |
| US-20020173507-A1 | Urea compounds and methods of uses | SLC14A1, UMPS, BAX | HRH3 2734/4885CYP2C19 1328/4885NCF1 1332/4885 |
| US-20070015759-A1 | Metasubstituted thiazolidinones, their manufacture and use as a drug | PLK4, PDXK, PLK2 | HRH3 4823/4885CYP2C19 334/4885NCF1 4228/4885 |
| US-20040044044-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | HRH3 3754/4885CYP2C19 1334/4885NCF1 2374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.